shiladit@mit.edu

Shiladitya Sengupta, PhD

HST Faculty

Assistant Professor of Medicine and Health Sciences and Technology, Harvard Medical School Brigham & Women's Hospital

Contact Information

(617) 768-8993

Lab Website

Degrees

Postdoctoral Associate, Massachusetts Institute of Technology, 2001-2005
PhD, University of Cambridge (Trinity College), 2002
MS, All India Institute of Medical Sciences, 1998
BS, All India Institute of Medical Sciences, 1996

Selected Awards/Societies

DoD Breast Cancer Research Program Collaborative Innovators Award (2009)
Mary Kay Ash Foundation Career Award (2007)
DoD Era of Hope Scholar Award (2007)
Indus Technovator Award (2006)
Coulter Foundation Young Investigator Award in Bioengineering (2006)
Technology Review 2005 TR35 Innovator Award
Young Investigator Award (2005), American Society for Pharmacology and Experimental Therapeutics
Postdoctoral Scientist Award (2003), American Society for Pharmacology and Experimental Therapeutics
Shakuntala Amir Chand Prize (1998) from Indian Council for Medical Research
Cambridge Nehru Scholarship (1998-2001)
Member, American Society for Pharmacology and Experimental Therapeutics
Member, American Association for Cancer Research

Research Interests

Our laboratory is interested in understanding the basic relationships at the cellular level that define a pathological state, and in using this knowledge to develop novel strategies or medicines for treating disease.

How does the cellular microenvironment modulate cellular functions or vice versa? Can the complex sugars that constitute the microenvironment play a cohesive role in intracellular regulation at the protein signaling or genetic levels? These are some key questions that we are probing using novel tools to dissect the complex sugars and connecting what we learn with changes we observe in genetic and protein-signaling. We are using this understanding to engineer novel therapeutic approaches for new drug discovery, for hybrid nanotechnology applications for novel therapeutic strategies, and for regenerative medicine using directed stem cell differentiation

Reference Publications

Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci U S A. 2009 May 12;106(19):7957-61. Featured on PNAS Highlights, Forbes, MSN News, CBS, The Telegraph, Yahoo News, Harvard Website.
Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br J Cancer. 2007 May 7;96(9):1315-9.
Sengupta S*, Eavarone DA*, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Novel cancer therapy through temporal targeting of both tumor cells and neovasculature using a unique nanoscale delivery system. Nature (2005) 436, 568-572. (*equal authors)
Sengupta S, Toh SA, Sellers LA, Skepper JN, Koolwijk P, Leung HW, Yeung HW, Wong RNS, Sasisekharan R, Fan TP. Modulating angiogenesis- The yin and the yang in ginseng. Circulation, (2004) 104: 1219-1225. Featured in Science Editor's Choice (10th Sep), Forbes (7th Sep), Washington Post (30th Aug), US Today, Petra (5th Sep, Greece), Folca (Brazil), Tech Review (Jan 05), U.S. Department of State release (31st Aug), NIGMS press release.
Sengupta S, Kiziltepe T, Sasisekharan R. A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules. FASEB J. 2004 Oct;18(13):1565-7.
Qi Y, Zhao G, Liu D, Shriver Z, Sundaram M, Sengupta S, Venkataraman G, Langer R, Sasisekharan R. Delivery of therapeutic levels of heparin and low molecular weight heparin through a pulmonary route. Proc. Natl. Acad. Sci. USA (2004) 101:9867-9872.
Johnson NA, Sengupta S, Saidi SA, Lessan K, Charnock-Jones SD, Scott L, Stephens R, Freeman TC, Tom BDM, Harris M, Denyer G, Sundaram M, Sasisekharan R, Smith SK, Print CG. Endothelial cells preparing to die by apoptosis initiate a program of transcriptome and glycome regulation. FASEB J. (2004) 18:188-190.
Sengupta S, Seller LA, Li R, Zhao G, Gherardi E, Sasisekharan R, Fan TP. Targeting of mitogen activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation (2003) 107: 2955-2961.

People

Faculty

shiladit@mit.edu